Safety and efficacy of nucle(t) side analogues for blocking mother-to-child transmission of HBV

WU Xiao-li; JIANG Jian-ning; SU Ming-hua; ZHONG Shao-hua; LI Shi-zhuang; WANG Bao-jian; LU Ai-lian; MO Yan-yan; LIANG Peng

doi:10.3969/j.issn.1002-266X.2015.06.007

Abstract：Objective To analyze the safety and efficacy of chronic hepatitis B ( CHB) patients in pregnancy with nu-cle(t)side analogues (NAs) treatment to block mother-to-child transmission of hepatitis B virus (HBV).Methods The 40 CHB patients before and/during pregnancy were treated with the NAs with informed consent , included 18 patients were treated with the NAs in the whole pregnancy or from the first trimester pregnancy ,17 patients were treated from the second trimester pregnancy , 5 patients were treated from the third trimester pregnancy .In drugs, 15 patients taked lamivudine ( LAM) , 23 patients taked telbivudine ( LDT) , 2 patients taked tenofovir ( TDF) ( without stopping treated before delivery with NAs dose of 1 capsule per day ) .HBV DNA and HBV serological markers were detected on a regular basis in pregnant women during pregnancy .The newborns were injected vaccine and immune globulin within 24 hours after birth , were detec-ted HBV DNA and /HBsAg in serum within 12 months of age.Results The 40 pregnant women delivered 44 infants, mothers and infants were safe .All the pregnant women during pregnancy hadn't adverse reactions to the NAs .With the anti-viral treatment,92.5% motherhood (37 women) intrapartum HBV DNA were equal or below 106 copies/ml,75%(30 women)were below 106 copies/ml.39 infants were detected HBV DNA and/HBsAg within 12 months of age,and they were all negative, 5 infants weren't detected.Except 1 infant had congenital heart disease diagnosis , 1 infant had malforma-tion of six fingers on left hand ( both had family history ) , the rest of infants development were normally .Conclusion In the first,second and third pregnancy , to block mother-to-child transmission of HBV by using pregnant class B NAs is effec-tive and safety .